Advertisement

Topics

Acucela Company Profile

17:02 EDT 24th September 2017 | BioPortfolio

Acucela Inc. (www.acucela.com) is a clinical-stage biotechnology company focused on leveraging promising science in visual cycle modulation (VCM) to develop new methods for treating blinding eye diseases that affect tens of millions of people worldwide. The Company’s orally delivered VCM compounds, which selectively target cells within the retina to protect visual acuity, have the potential to treat several devastating eye diseases, including dry AMD, for which there is currently no treatment options, retinopathy of prematurity, Stargardt disease and diabetic retinopathy. ACU-4429 for dry AMD is being co-developed by Acucela and Otsuka Pharmaceutical Co., Ltd. in North America, and the companies are also co-developing Rebamipide for dry eye and OPA-6566 for glaucoma in the United States. Acucela was founded by Ryo Kubota, M.D., Ph.D., a pioneer in ophthalmology and the discoverer of the gene that causes glaucoma.


News Articles [4 Associated News Articles listed on BioPortfolio]

Patent granted for method of use of Acucela’s Stargardt disease treatment

The U.S. Patent and Trademark Office granted U.S. Patent No. 9,737,496 B2 to Acucela for method of use of its Stargardt disease treatment emixustat hydrochloride or a “broad number of related compou...

Acucela Granted New Patent Covering Method of Use for Emixustat Hydrochloride

Acucela Inc. (“Acucela”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) committed to translating ...

Acucela Inc 4589 Pharmaceuticals Healthcare Deals and Alliances Profile. [Report Updated: 20072017] Prices from USD $250

SummaryAcucela Inc Acucela, a subsidiary of Kubota Pharmaceutical Holdings Co Ltd, is a clinical stage ophthalmology company which discovers and develops novel therapeutics for the treatment of sight ...

Cataract Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $1250

DelveInsight's, Cataract Pipeline Insights, 2017, report provides comprehensive insights about pipeline drugs across this Cataract. The key objective of the report is to establish the understanding f...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [3 Associated Companies listed on BioPortfolio]

Acucela Inc.

Acucela Inc. is a clinical-stage biotechnology company focused on leveraging promising science in visual cycle modulation (VCM) to develop new methods for treating blinding eye di...

Acucela Inc

Acucela Inc. is a biotech company discovering new drug therapies for eye diseases. Neurodegenerative retinal diseases such as macular degeneration, Stargardt's disease, retinitis pigmentosa and glauco...

Acucela

Acucela Inc. (www.acucela.com) is a clinical-stage biotechnology company focused on leveraging promising science in visual cycle modulation (VCM) to develop new methods for...

More Information about "Acucela" on BioPortfolio

We have published hundreds of Acucela news stories on BioPortfolio along with dozens of Acucela Clinical Trials and PubMed Articles about Acucela for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Acucela Companies in our database. You can also find out about relevant Acucela Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...


Corporate Database Quicklinks



Searches Linking to this Company Record